10-K: Oaktree SPAC Reports Net Income, Faces Going Concern Doubt

Oaktree Acquisition Corp. III Life Sciences, a blank check company, reported net income for 2025 but faces substantial doubt about its ability to continue as a going concern due to its business combination deadline.

Summary

• Oaktree Acquisition Corp. III Life Sciences is a blank check company formed on June 28, 2024, with the objective of completing a business combination, primarily targeting the healthcare or healthcare-related industries in North America, British, or European markets.
• The company has no operating history or revenues to date, with its efforts focused on organizational activities and the search for an initial business combination.
• As of December 31, 2025, the company reported a net income of $7,288,824, primarily from $8,484,511 in interest earned on cash held in its trust account, offset by $1,195,687 in general and administrative expenses.
• A total of $201,563,532 was held in the trust account as of December 31, 2025, with $1,434,965 in cash available outside the trust account for working capital.
• The company must complete a business combination by October 25, 2026, which is 24 months from its Initial Public Offering closing.
• The independent registered public accounting firm's report expresses substantial doubt about the company's ability to continue as a going concern due to the proximity of its liquidation deadline if a business combination is not consummated.
• The sponsor, Oaktree Acquisition Holdings III LS, LLC, holds 4,799,758 Class B ordinary shares and 583,981 private placement units, representing a significant voting interest and potential for substantial profit even if public shares decline.
• Management has prior SPAC experience, including successful de-SPACing acquisitions of Hims & Hers Health, Inc. and Alvotech, with a mean return of approximately 117% since their respective IPOs as of January 7, 2026.
• The company's acquisition strategy leverages Oaktree's global investment platform, extensive network, and expertise in healthcare and life sciences, aiming for targets with enterprise values between $500 million and $1.5 billion.
• Deferred underwriting commissions of $6,719,660 are payable to underwriters only upon the completion of a business combination.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with caution due to the explicit 'going concern' warning from the auditor and the inherent risks of SPACs, despite the management team's strong track record and Oaktree's backing. The lack of an identified target and the looming deadline contribute to the uncertainty.

Positives

• The company reported a net income of $7,288,824 for the year ended December 31, 2025, primarily from interest earned on its trust account.
• The management team and board of directors possess extensive experience in financial reporting, corporate governance, risk management, and strategic business analysis, particularly within the healthcare sector.
• Oaktree, the sponsor's affiliate, is a leading global investment management firm with approximately $223 billion in assets under management as of December 31, 2025, providing significant resources and network access.
• The management team has a successful track record with prior SPACs, including Hims & Hers Health, Inc. (NYSE: HIMS) and Alvotech (NASDAQ: ALVO), which generated a mean return of approximately 117% since their IPOs as of January 7, 2026.
• The company intends to focus on the healthcare or healthcare-related industries, which have historically benefited from attractive secular growth and technological innovation.
• The company has $201,563,532 in its trust account as of December 31, 2025, available for a business combination.

Negatives

• The independent auditor's report expresses substantial doubt about the company's ability to continue as a going concern due to the mandatory liquidation date if a business combination is not completed by October 25, 2026.
• The company has no operating history or revenues, making it difficult for investors to evaluate its ability to achieve its business objective.
• The nominal purchase price paid by the sponsor for founder shares ($0.005 per share) may result in significant dilution to public shareholders upon a business combination, creating an incentive for the sponsor to complete a transaction even if it is unprofitable for public shareholders.
• Public shareholders may not have the opportunity to vote on a proposed business combination, and the sponsor's voting power (approximately 20% of ordinary shares) increases the likelihood of approval regardless of public shareholder sentiment.
• The ability of public shareholders to redeem shares for cash may make the company's financial condition unattractive to potential target businesses, potentially hindering the completion of a desirable business combination.
• The 24-month deadline for completing a business combination may give potential target businesses leverage in negotiations and limit the time for due diligence.
• Geopolitical conflicts (Russia-Ukraine, Israel-Hamas, US-Venezuela, Middle East-Iran) and macro-economic turbulence (inflation, interest rates) could adversely affect the search for a business combination and the performance of a target business.
• The company may need to obtain additional financing to complete a business combination or fund the target's operations, which may not be available on acceptable terms or could lead to dilutive equity issuances or substantial debt.

Risks

• No operating history and no revenues, providing no basis to evaluate the ability to achieve business objectives.
• Inability to complete an initial business combination within 24 months (by October 25, 2026) would lead to liquidation, and warrants would expire worthless.
• Public shareholders may not be afforded an opportunity to vote on the proposed initial business combination.
• Sponsor and management team have agreed to vote in favor of a business combination, regardless of how public shareholders vote.
• The ability of public shareholders to redeem shares for cash may make the financial condition unattractive to potential targets.
• Large redemptions could prevent the completion of the most desirable business combination or optimize capital structure, and substantially dilute non-redeeming shareholders.
• Sponsor, directors, officers, advisors, or their affiliates may purchase shares or warrants from public shareholders, potentially influencing a vote and reducing public float.
• Shareholders may lose the ability to redeem 'Excess Shares' (more than 15% of public shares) without prior consent.
• Competition from other SPACs and private equity groups for attractive target businesses.
• Insufficient funds outside the trust account to operate for the full 24-month period, requiring reliance on sponsor loans.
• Past experience of management or Oaktree is not indicative of future performance.
• No rights or interests in funds from the trust account, except under limited circumstances.
• Warrant terms may be amended adversely to public holders with approval of 50% of outstanding public warrants.
• Warrants may be redeemed prior to their exercise at a disadvantageous time, making them worthless.
• Nasdaq may delist securities, limiting trading ability and subjecting the company to additional restrictions.
• Nominal purchase price paid by the sponsor for founder shares may result in significant dilution to public shares.
• Potential classification as a Passive Foreign Investment Company (PFIC) could result in adverse U.S. federal income tax consequences for U.S. investors.
• Difficulties in protecting interests and enforcing rights through U.S. Federal courts due to Cayman Islands incorporation.
• Executive officers, directors, security holders, and their affiliates may have competitive pecuniary interests that conflict with the company's interests.
• Independent registered public accounting firm's report contains an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern.
• Business combinations may involve high complexity and require significant operational improvements, which could delay or prevent desired results.
• Shareholders may be held liable for claims by third parties against the company to the extent of distributions received upon redemption.
• The company may not hold an annual meeting of shareholders until after the consummation of its initial business combination.
• Acquisition opportunities may be in industries or sectors outside of management's direct expertise.
• Healthcare industry specific risks, including governmental regulation, cost control pressures, product liability, and patent expirations.
• No specified maximum redemption threshold, allowing completion of a business combination even if a majority of public shareholders disagree.
• Charter and governing instrument amendments may be easier to pass than in some other blank check companies.
• Inability to obtain additional financing to complete a business combination or fund target business operations and growth.
• Securities in the trust account could bear a negative rate of interest, reducing the per-share redemption amount.
• Warrants may become exercisable and redeemable for a security other than Class A ordinary shares.
• Warrants may not be exercisable unless underlying Class A ordinary shares are registered or exemptions are available.
• Members of management team and affiliated companies may be involved in civil disputes or governmental investigations unrelated to the business.
• The letter agreement with the sponsor, officers, and directors may be amended without shareholder approval, potentially leading to loss of key personnel.
• The recent 1% U.S. federal excise tax on stock buybacks could be imposed on redemptions of shares if the company becomes a covered corporation.
• The initial business combination and subsequent structure may not be tax-efficient to shareholders, potentially requiring them to recognize taxable income.
• Reincorporation in another jurisdiction may result in taxes imposed on shareholders and warrant holders.
• Changes in laws or regulations, or failure to comply, may adversely affect the business, including the 2024 SPAC Rules.
• Risks associated with acquiring and operating a business in foreign countries, including currency fluctuations, political instability, and legal system unpredictability.

Future Outlook

The company's future outlook is entirely dependent on successfully identifying and completing an initial business combination within the stipulated 24-month period (by October 25, 2026). It expects to leverage Oaktree's platform and management's expertise to find a suitable target in the healthcare or healthcare-related industries. The company anticipates incurring significant costs in pursuit of its acquisition plans and may need additional financing. There is no assurance that a business combination will be successful.

Management Comments

• "We believe our management team is well suited to identify opportunities that have the potential to generate attractive risk-adjusted returns for our shareholders."
• "Through our affiliation with Oaktree, we intend to capitalize on the ability and experience of the Oaktree platform across healthcare or healthcare-related industries."
• "We believe that the breadth of the Oaktree platform and the collective expertise of our management team will allow us to identify numerous initial acquisition targets across the healthcare or healthcare-related sectors."
• "We believe having a deep understanding of, ability to speak the language, and relationships within the life sciences industry provides a significant advantage when negotiating with management teams and evaluating prospective business combination targets."
• "We intend to employ a fundamental, value-oriented acquisition framework that seeks a target with the potential for significant equity value creation coupled with strong downside protection from dependable cash flows and a durable business franchise."
• "We do not expect these duties [conflicts of interest] to present a significant conflict of interest with our search for an initial business combination. We believe this conflict of interest will be naturally mitigated, to some extent, by the differing nature of the acquisition targets Oaktree typically considers most attractive for Oaktree funds and the types of acquisitions we expect Oaktree Acquisition Corp. III Life Sciences to find most attractive."

Industry Context

StockSavvy.ai notes that Oaktree Acquisition Corp. III Life Sciences' focus on the healthcare and life sciences sectors aligns with broader industry trends of continuous innovation, rapid technological advancements, and favorable demographic tailwinds. The company aims to capitalize on Oaktree's established reputation and extensive network, which has a proven track record in this space, including successful de-SPAC transactions with Hims & Hers Health, Inc. and Alvotech. This strategic alignment with a high-growth, capital-intensive industry, coupled with Oaktree's deep investment and operational expertise, positions the SPAC to potentially identify attractive targets despite increased competition in the SPAC market.

Comparison to Industry Standards

• Oaktree's Life Sciences investment platform has committed approximately $6.2 billion across 54 life sciences investments since 2013 with no realized losses, indicating a strong historical performance in the sector.
• The management team's prior SPACs, Oaktree Acquisition Corp. (Hims & Hers Health, Inc.) and Oaktree Acquisition Corp. II (Alvotech), generated a mean return of approximately 117% since their respective IPOs as of January 7, 2026, which is a notable performance compared to the often mixed results of other SPACs.
• The redemption rate for Oaktree Acquisition Corp. (Hims, Inc.) was very low at approximately 0.03% (6,193 Class A ordinary shares redeemed), suggesting strong shareholder confidence in that particular business combination.
• In contrast, Oaktree Acquisition Corp. II (Alvotech) experienced a high redemption rate of approximately 96.09% (24,023,495 Class A ordinary shares redeemed), highlighting the variability in shareholder reception for SPAC business combinations.
• The target enterprise value range of $500 million to $1.5 billion is typical for SPACs seeking to acquire established, yet growing, private companies.

Management Changes

Corporate Governance

Legal Proceedings

• No material litigation currently pending or contemplated against the company, its officers, or directors.

Related Party Transactions

• The sponsor, Oaktree Acquisition Holdings III LS, LLC, paid $25,000 for 4,799,758 founder shares (Class B ordinary shares).
• The sponsor purchased 583,981 private placement units for $5,839,810.
• The company pays the sponsor $25,000 per month for office space, secretarial, and administrative services, commencing October 23, 2024.
• The company has an administrative services and indemnification agreement with the sponsor, indemnifying the sponsor and its affiliates (including Oaktree) from certain liabilities.
• The sponsor or its affiliates may loan the company funds for working capital (up to $1,500,000), convertible into private placement units at $10.00 per unit.
• The sponsor and its permitted transferees are entitled to certain registration rights for their securities and the right to nominate three directors post-business combination.
• Independent directors (Paul Meister, Alvin Shih, David Berry) were offered the opportunity to make a non-controlling minority investment in the sponsor.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from founder shares and potential future equity issuances. Public shareholders may have limited voting power and redemption rights. The 'going concern' warning poses a direct risk to their investment.
• **Sponsor/Management:** Have substantial economic interests and voting control, creating potential conflicts of interest. They stand to make significant profits if a business combination is completed, even if public share value declines.
• **Underwriters:** Are entitled to deferred underwriting commissions of $6,719,660 only upon the completion of a business combination, creating an incentive for them to facilitate a transaction.
• **Creditors:** The trust account is designed to protect public shareholders, but there's a risk that third-party claims could reduce the funds available for redemption, potentially making public shareholders liable for claims if the company liquidates.

Next Steps

• Identify and evaluate a suitable target business or businesses for an initial business combination.
• Complete an initial business combination by October 25, 2026.
• Potentially seek shareholder approval to amend the memorandum and articles of association to extend the business combination deadline if needed.
• Potentially seek additional financing (equity or debt) to complete a business combination or fund the target's operations.
• File a registration statement covering Class A ordinary shares issuable upon exercise of warrants within 20 business days after closing of the initial business combination.

Key Dates

Recommendation

The company is a blank check company with no operations, and its future is entirely dependent on a successful business combination. While the management team has a strong track record with prior SPACs and Oaktree's backing provides a robust network, the explicit 'going concern' warning from the auditor is a significant red flag. The looming deadline for a business combination (October 25, 2026) and potential dilution for public shareholders add considerable uncertainty. Given these factors, a 'hold' recommendation is appropriate for existing investors who understand the speculative nature of SPACs and are willing to wait for a potential business combination announcement, while new investors should exercise extreme caution due to the high risks involved.

Keywords

SPAC, Blank Check Company, Healthcare, Life Sciences, Business Combination, Oaktree, SEC Filing, 10-K, Trust Account, Warrants, Dilution, Going Concern, Corporate Governance, Risk Factors, Financial Reporting, Nasdaq, Biopharmaceutical, Medical Devices, Diagnostics, Specialized Healthcare Services